Skip to content
AnalystLens

AMGEN INC 8-K Report, Financial Results (Oct 30, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 30, 2024
Period End
October 30, 2024
Security
AMGN
In the record · 2016–202610-K1210-Q328-K125

AMGN filed 12 annual reports (10-K), 32 quarterly reports (10-Q) and 125 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’17Oct ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Material agreement8-K · Feb ’22Feb ’22
  4. Cybersecurity incident8-K · Jul ’26Jul ’26

01—Abstract

Summary

Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Amgen's third quarter 2024 results (reported October 30, 2024) showed strong top-line momentum and a sharp rise in GAAP earnings, but the quality of the GAAP profit picture is distorted by non-cash items.

Total revenues rose 23% to $8.5 billiona, and product sales grew 24% to $8.15 billion. Excluding the Horizon Therapeutics acquisition, product sales grew 8%, with volume up 12%, so the underlying organic growth is more modest than the headline suggests. Ten products posted at least double-digit growth, and rare disease sales reached $1.2 billion, led by TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS.

GAAP diluted EPS rose 62% to $5.22b, but this was driven mainly by a $1.6 billion mark-to-market gain on the BeiGene equity stake rather than operating performance. GAAP operating income was roughly flat at $2.0 billion, and GAAP operating margin fell 5.8 points to 25.1%, reflecting heavy Horizon-related amortization. Non-GAAP EPS rose 13% to $5.58, and non-GAAP operating margin of 49.6% declined 2.4 points, as incremental Horizon expenses and higher interest expense absorbed much of the revenue gain.

Investors should focus on non-GAAP metrics and the free cash flow of $3.3 billionc as the cleaner read on the business. Balance sheet deleveraging continued, with $2.5 billion of principal debt repaid in the quarter and $4.5 billion year-to-date, bringing debt outstanding to $60.4 billion against $9.0 billion of cash and investments.

The company raised its full-year 2024 guidance: revenues of $33.0d–33.8 billion, non-GAAP EPS of $19.20–$20.00, and GAAP EPS of $8.71–$9.56. Pipeline updates included positive Phase 3 HORIZON data for rocatinlimab in atopic dermatitis, an FDA Breakthrough Therapy Designation for UPLIZNA in IgG4-related disease, and continued Phase 3 development of MariTide for obesity, with Phase 2 topline data expected in late 2024.

02—Key points

Key Highlights

  1. Total revenues up 23% year-over-year to $8.5 billion; product sales up 24% to $8.15 billion, but only 8% growth excluding Horizon.
  2. GAAP diluted EPS up 62% to $5.22, driven largely by a mark-to-market gain on the BeiGene equity investment rather than operations.
  3. Non-GAAP diluted EPS up 13% to $5.58; non-GAAP operating margin declined 2.4 points to 49.6% due to Horizon-related expenses and higher interest expense.
  4. Free cash flow of $3.3 billion, up from $2.5 billion, supported by business performance and working capital timing.
  5. Debt reduced by $2.5 billion in Q3 and $4.5 billion year-to-date; debt outstanding of $60.4 billion versus $9.0 billion in cash and investments.
  6. FY2024 guidance updated: revenue $33.0–33.8 billion, non-GAAP EPS $19.20–$20.00, GAAP EPS $8.71–$9.56, capex about $1.3 billion, buybacks capped at $500 million.
  7. Pipeline progress includes positive Phase 3 HORIZON data for rocatinlimab in atopic dermatitis, UPLIZNA Breakthrough Therapy Designation for IgG4-RD, and an upcoming MariTide Phase 2 readout in late 2024.

03—Questions

Frequently Asked Questions

  1. Why did GAAP EPS rise 62% while GAAP operating income was flat?

    The increase was driven mainly by a $1.6 billion mark-to-market gain on Amgen's BeiGene equity investment, recorded in other income, rather than by operating results. GAAP operating income was essentially unchanged at $2.0 billion because Horizon-related amortization and expenses offset higher revenue.

  2. How much of the revenue growth came from the Horizon acquisition?

    Most of it. Total product sales grew 24%, but excluding Horizon-acquired products, growth was 8%, with volume up 12%. The acquisition therefore accounts for roughly two-thirds of the reported product sales growth.

  3. Is Amgen's financial position improving?

    Partly. The company reduced debt by $4.5 billion year-to-date and generated $3.3 billion of free cash flow in the quarter. However, total debt of $60.4 billion remains high relative to $9.0 billion of cash and investments, and interest expense of $776 million in the quarter continues to weigh on non-GAAP earnings.

  4. What are the key risks to Amgen's growth outlook?

    Key risks include declining Enbrel sales (down 20% with continued net price erosion expected), MVASI erosion from biosimilar competition, ongoing volume declines in established products, and the execution risk of integrating Horizon. Pipeline readouts, such as rocatinlimab's additional Phase 3 data and MariTide's Phase 2 results, also carry binary risk.

04—Continue

← View all 8-K filings